The added benefits of weight loss, less insulin doses, daily injections, and hypoglycemia, accompanied by increased patients’ satisfaction related to therapy modifications, were maintained in the extension period in at least one-half of the randomized patients. This evidence concerns the gene INS and Hypoglycemia.